GeoVax (GOVX) CEO On Developing A Covid-19 Vaccine

<p>GeoVax (GOVX) stock is down around 11% in the last 5 days. Chairman and CEO, David Dodd, says that the clinical stage biotech company develops immunotherapies and vaccines against cancers and infectious diseases. GeoVax has Covid-19 trials for immunocompromised patients and a booster for MRNA treatment. </p><p><br></p>